Jason Szabo

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients

Élise Vuille‐Lessard, Bertrand Lebouché, Lynda Lennox et al. · AIDS · 2016 · 100 citations

Medicine, Infectious Diseases, Pathology +17

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 91 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection

Vikram Mehraj, Rayoun Ramendra, Stéphane Isnard et al. · Frontiers in Immunology · 2019 · 63 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education

Cecilia T. Costiniuk, Zahra Saneei, Syim Salahuddin et al. · Cannabis and Cannabinoid Research · 2019 · 62 citations · Full text

Public Health, Health Behavior, Health Education +16